vs
Side-by-side financial comparison of ABVC BIOPHARMA, INC. (ABVC) and Pelican Acquisition Corp (PELI). Click either name above to swap in a different company.
Pelican Acquisition Corp is the larger business by last-quarter revenue ($888.8K vs $796.0K, roughly 1.1× ABVC BIOPHARMA, INC.). Pelican Acquisition Corp runs the higher net margin — 57.9% vs -256.6%, a 314.5% gap on every dollar of revenue. On growth, ABVC BIOPHARMA, INC. posted the faster year-over-year revenue change (104.5% vs 39.8%).
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.
Pelican Products is an American multinational company that designs and manufactures portable lighting systems, temperature controlled packaging and protective cases. Their products are used in many industries including military, law enforcement, fire safety, and consumer entertainment. The company's flagship product, Pelican cases, are molded plastic cases that seal with an airtight and watertight gasket. Pelican is based in Torrance, California. In Europe the products are branded Peli.
ABVC vs PELI — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $796.0K | $888.8K |
| Net Profit | $-2.0M | $514.6K |
| Gross Margin | 100.0% | — |
| Operating Margin | -246.8% | -42.2% |
| Net Margin | -256.6% | 57.9% |
| Revenue YoY | 104.5% | 39.8% |
| Net Profit YoY | -417.4% | 67.4% |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $888.8K | ||
| Q3 25 | $796.0K | $635.7K | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | — | ||
| Q2 24 | $117.1K | — | ||
| Q1 24 | $1.2K | — | ||
| Q4 23 | $2.2K | — | ||
| Q3 23 | $15.9K | — |
| Q4 25 | — | $514.6K | ||
| Q3 25 | $-2.0M | $307.4K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-394.8K | — | ||
| Q2 24 | $-942.3K | — | ||
| Q1 24 | $-2.8M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-3.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | 100.0% | — | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | 77.0% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | -42.2% | ||
| Q3 25 | -246.8% | -52.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | — | ||
| Q1 24 | -235539.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -13566.3% | — |
| Q4 25 | — | 57.9% | ||
| Q3 25 | -256.6% | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | — | ||
| Q1 24 | -235203.2% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -20885.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.09 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.29 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $257.2K | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $12.1M | $-31.2K |
| Total Assets | $21.2M | $88.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $257.2K | — | ||
| Q4 24 | $313.1K | — | ||
| Q3 24 | $208.2K | — | ||
| Q2 24 | $200.0K | — | ||
| Q1 24 | $106.4K | — | ||
| Q4 23 | $139.5K | — | ||
| Q3 23 | $568.6K | — |
| Q4 25 | — | $-31.2K | ||
| Q3 25 | $12.1M | $342.9K | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $1.7M | — | ||
| Q4 23 | $1.6M | — | ||
| Q3 23 | $9.1M | — |
| Q4 25 | — | $88.1M | ||
| Q3 25 | $21.2M | $87.3M | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $8.0M | — | ||
| Q4 23 | $7.8M | — | ||
| Q3 23 | $16.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-964.7K | $-367.8K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.71× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-367.8K | ||
| Q3 25 | $-964.7K | $-420.4K | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $60.2K | — | ||
| Q2 24 | $-211.4K | — | ||
| Q1 24 | $-955.8K | — | ||
| Q4 23 | $-4.2M | — | ||
| Q3 23 | $-1.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-4.2M | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -194367.2% | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 979.3% | — | ||
| Q3 23 | — | — |
| Q4 25 | — | -0.71× | ||
| Q3 25 | — | -1.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
